Gene expression data from FlyAtlas and the Berkeley Drosophila Genome Project in situ project suggest that most Drosophila Smyd proteins are expressed specifically in muscle, brain or sex specific tissues (Table S1) Supplementary Table 1; [24], [24].
The four enriched terms with the smallest p-value of each grouping using the Berkeley Drosophila Genome Project in situ database comparison are displayed in Table 1 (complete results available in Additional file 3).
A mixed-methods approach was taken in the development phase of the project; in situ simulation was used to evaluate the effectiveness of the newly developed IDEAS prescription chart.
To calculate enrichment of gene groups for their first expression in specific tissues, we downloaded the Berkeley Drosophila Genome Project in situ expression database from http://insitu.fruitfly.org/ (Tomancak et al., 2002, 2007).
Of the 4202 D. melanogaster genes from the Berkeley Drosophila Genome Project in situ database with T. castaneum orthologs, 3718 (88.5%) of the D. melanogaster genes had associated gene ontologies.
Additional lists of maternal D. melanogaster genes were generated with FlyMine v32.0 (http://www.flymine.org, [ 35]) using the mRNA expression term "maternal" for the Berkeley Drosophila Genome Project in situ database [ 24, 25] and Fly-Fish database [ 26].
Of the 3718 D. melanogaster genes with associated gene ontologies, 3235 (87.0%) were in group A, 184 (4.9%) were in group B, and 299 (8.0%) were in group C. The four enriched molecular function terms with the lowest p-values for each group within the comparison of the Berkeley Drosophila Genome Project in situ database maternal genes to the T. castaneum findings.
Only the Berkeley Drosophila Genome Project in situ database [ 24, 25] had a sufficient number of genes and distribution among gene groupings (i.e. Group A, maternally loaded; Group B, fertilized expressed; Group C, not expressed) for the enrichment test to provide enriched terms for all of the comparison groupings.
With its new-found capital, Ciris specificially plans to build its first commercial-scale projects for "in-situ biochemical conversion of coal to methane," and to bring its "ex-situ biochemical coal conversion technology to commercial-ready status," the company said in a press statement.
The overall research project involved in situ measurements, extensive simulation work and design guide calculations of heat loss through the ground from different real buildings.
